

Attorney Docket No.: 5218-39B

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Anagnostou et al.

Group Art Unit: 1642

Application Serial No.: 09/525,797

Examiner: Susan Unger

Filed: March 15, 2000

Confirmation No.: 9917

For: METHOD OF TREATING ENDOTHELIAL INJURY

Date: November 29, 2006

Mail Stop AF

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(d)**

Dear Sir:

Attached is a list of documents on form PTO-1449 together with a copy of each identified document. Also enclosed is a translation or a concise explanation of each non-English language document. This Information Disclosure Statement is being filed in accordance with the requirements of 37 C.F.R. 1.97(d).


In accordance with the requirements of 37 C.F.R. § 1.97(d)(1), the following certification as specified in 37 C.F.R. § 1.97(e)(1) is made:

Each item of information contained in this Information Disclosure Statement was first cited in a communication presented to a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement, and more specifically, during an Opposition Proceeding in corresponding European Patent No. 0933995 (European Patent Application No. 97940974.5).

In accordance with the requirements of 37 C.F.R. § 1.97(d)(2), the Commissioner is authorized to charge \$180.00 to Deposit Account No. 50-0220 for the fee specified in 37 C.F.R. § 1.17(p). This amount is believed to be correct; however, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.


Myers Bigel Sibley & Sajovec, P.A.  
P. O. Box 37428, Raleigh, NC 27627  
Telephone: (919) 854-1400  
Facsimile: (919) 854-1401  
Customer No. 20792

Respectfully Submitted,

  
Shawna Cannon Lemon  
Registration No. 53,888

**CERTIFICATION OF ELECTRONIC TRANSMISSION  
UNDER 37 CFR § 1.8**

I hereby certify that this correspondence is being transmitted electronically to the U.S. Patent and Trademark Office on November 29, 2006.

  
Evelyn B. Casey; Date of Signature: November 29, 2006

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1 of 1
-------	--------

Application Number	09/525,797
Filing Date	March 15, 2000
First Named Inventor	Anagnostou et al.
Group Art Unit	1642
Examiner Name	Susan Ungar
Attorney Docket Number	5218-39B

[illegible]

Examiner Initials*	Cite No.	U.S. Serial No.	Name of Applicant of Cited Document	Date of Filing of Cited Document MM-DD-YYYY
		US-		
		US-		
		US-		
		US-		

[illegible]

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
/KAC/	1.	Breyman et al. "Optimal timing of repeated rh-erythropoietin administration improves its effectiveness in stimulating erythropoiesis in healthy volunteers" <i>Br J Haematol.</i> 92(2):295-301 (1996)	
/KAC/	2.	Ito et al. "Vitamin E prevents endothelial injury associated with cisplatin injection into the superior mesenteric artery of rats" <i>Heart Vessels</i> 10(4):178-84 (1995)	
/KAC/	3.	Komatsu-moto et al. "Multiple cerebral infarction after treatment with cisplatin" <i>Rinsho Shinkeigaku</i> 36(3):499-502 (1996)	abstract

/Karen A. Canella, Ph.D./

08/18/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.